MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592612 | Name: Cimoxatone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cimoxatone is a Monoamine Oxidase Inhibitor.

Chemical Structure

Cimoxatone
Cimoxatone
CAS#73815-11-9

Theoretical Analysis

MedKoo Cat#: 592612

Name: Cimoxatone

CAS#: 73815-11-9

Chemical Formula: C19H18N2O4

Exact Mass: 338.1267

Molecular Weight: 338.36

Elemental Analysis: \C, 67.45; H, 5.36; N, 8.28; O, 18.91

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Cimoxatone; MD 780515; MD-780515; MD780515
IUPAC/Chemical Name
alpha-(p-(5-(Methoxymethyl)-2-oxo-3-oxazolidinyl)phenoxy)-m-tolunitrile
InChi Key
MVVJINIUPYKZHR-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H18N2O4/c1-23-13-18-11-21(19(22)25-18)16-5-7-17(8-6-16)24-12-15-4-2-3-14(9-15)10-20/h2-9,18H,11-13H2,1H3
SMILES Code
N#CC1=CC=CC(COC2=CC=C(N3C(OC(COC)C3)=O)C=C2)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 338.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dollery CT, Brown MJ, Davies DS, Lewis PJ, Strolin-Benedetti M. Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase. Clin Pharmacol Ther. 1983 Nov;34(5):651-62. PubMed PMID: 6627826. 2: Rovei V, Mitchard M, Strolin Benedetti M, Kendall MJ. Pharmacokinetic and relative bioavailability studies of cimoxatone in humans. Int J Clin Pharmacol Ther Toxicol. 1984 Jan;22(1):56-62. PubMed PMID: 6698662. 3: Rovei V, Chanoine F, Strolin Benedetti M, Zini R, Tillement JP. Plasma protein binding of the reversible type A MAO inhibitor cimoxatone (MD 780515). Biochem Pharmacol. 1983 Aug 1;32(15):2303-8. PubMed PMID: 6192825. 4: Fowler CJ, Strolin Benedetti M, Rovei V. Estimation of the elimination half-life of the monoamine oxidase inhibitor cimoxatone in rat brain on the basis of ex vivo inhibition data. Eur J Drug Metab Pharmacokinet. 1983 Oct-Dec;8(4):389-93. PubMed PMID: 6673976. 5: Poirier MF, Olié JP, Lôo H, Deniker P, Strolin Benedetti M, Rovei V, Lesage A. [Antidepressive action, pharmacokinetic characteristics and biochemical properties of cimoxatone, a new reversible MAO-A inhibitor]. Encephale. 1983;9(4):331-43. French. PubMed PMID: 6368197. 6: Garrick NA, Seppala T, Linnoila M, Murphy DL. Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone. Psychopharmacology (Berl). 1985;86(3):265-9. PubMed PMID: 2412251. 7: Fowler CJ, Strolin Benedetti M. Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase. J Neurochem. 1983 Feb;40(2):510-3. PubMed PMID: 6822834. 8: Rovei V, Rigal M, Sanjuan M, Thiola A. High-performance liquid chromatographic determination of cimoxatone and its O-demethyl metabolite in plasma. J Chromatogr. 1983 Oct 14;277:391-5. PubMed PMID: 6643627. 9: Fowler CJ, Benedetti MS. The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone. J Neurochem. 1983 Jun;40(6):1534-41. PubMed PMID: 6406646. 10: Strolin Benedetti M, Eschalier A, Lesage A, Dordain G, Rovei V, Zarifian E, Dostert P. Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man. Eur J Clin Pharmacol. 1984;26(1):71-7. PubMed PMID: 6538844. 11: Strolin Benedetti M, Boucher T, Fowler CJ. The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222. Naunyn Schmiedebergs Arch Pharmacol. 1983 Aug;323(4):315-20. PubMed PMID: 6633672. 12: Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. J Pharmacol Exp Ther. 1987 Jan;240(1):251-8. PubMed PMID: 3100771. 13: Waldmeier PC. On the reversibility of reversible MAO inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 1985 May;329(3):305-10. PubMed PMID: 4022138. 14: Finberg JP, Youdim MB. Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase. J Neural Transm Suppl. 1988;26:11-6. PubMed PMID: 3162950. 15: Burkard WP, Bonetti EP, Da Prada M, Martin JR, Polc P, Schaffner R, Scherschlicht R, Hefti F, Müller RK, Wyss PC, et al. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther. 1989 Jan;248(1):391-9. PubMed PMID: 2913284. 16: Fletcher PJ, Yu PH. Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors. Psychopharmacology (Berl). 1989;98(2):265-8. PubMed PMID: 2502797. 17: Benedetti MS, Boucher T, Carlsson A, Fowler CJ. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem Pharmacol. 1983 Jan 1;32(1):47-52. PubMed PMID: 6830619. 18: Kan JP, Mouget-Goniot C, Worms P, Biziere K. Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat. Biochem Pharmacol. 1986 Mar 15;35(6):973-8. PubMed PMID: 3954800. 19: Delini-Stula A, Radeke E, Waldmeier PC. Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. Psychopharmacol Ser. 1988;5:147-58. Review. PubMed PMID: 3045798. 20: Benedetti MS, Ancher JF, Sontag N. Monoamine oxidase inhibitors and histamine metabolism. Experientia. 1980 Jul 15;36(7):818-10. PubMed PMID: 6772465.